Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma

被引：0
作者：
Dummer, Reinhard
Robert, Caroline
Nyakas, Marta
McArthur, Grant A.
Kudchadkar, Ragini Reiney
Gomez-Roca, Carlos
Sullivan, Ryan J.
Flaherty, Keith
Murer, Carla
Michel, Daniela
Tang, Zhongwen
De Parseval, Laure A.
Delord, Jean-Pierre
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] Inst Gustave Roussy, Villejuif, France
[3] Oslo Univ Hosp, Oslo, Norway
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[6] Inst Claudius Regaud, Toulouse, France
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9028
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PHASE 1/2 STUDY OF GSK2118436, A SELECTIVE INHIBITOR OF V600 MUTANT (MUT) BRAF KINASE: EVIDENCE OF ACTIVITY IN MELANOMA BRAIN METASTASES (METS)
    Long, G. V.
    Kefford, R. F.
    Carr, P. J. A.
    Brown, M. P.
    Curtis, M.
    Ma, B.
    Lebowitz, P.
    Kim, K. B.
    Kurzrock, R.
    Falchook, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [32] Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
    Schreuer, Max
    Jansen, Yanina
    Planken, Simon
    Chevolet, Ines
    Seremet, Teofila
    Kruse, Vibeke
    Neyns, Bart
    LANCET ONCOLOGY, 2017, 18 (04) : 464 - 472
  • [33] A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.
    Patel, Manish R.
    Fakih, Marwan
    Olszanski, Anthony J.
    Lockhart, Albert C.
    Drilon, Alexander E.
    Fu, Siqing
    Bazhenova, Lyudmila
    Patel, Rupal
    Oliver, Jennifer W.
    Multani, Pratik S.
    Wang, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).
    Long, Georgina V.
    Eroglu, Zeynep
    Infante, Jeffrey R.
    Patel, Sapna Pradyuman
    Daud, Adil
    Johnson, Douglas Buckner
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn Mara
    Cebon, Jonathan S.
    Sharfman, William Howard
    McWilliams, Robert R.
    Sznol, Mario
    Weber, Jeffrey S.
    Mookerjee, Bijoyesh
    Gasal, Eduard
    Redhu, Suman
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    Ascierto, Paolo A.
    Schadendorf, Dirk
    Berking, Carola
    Agarwala, Sanjiv S.
    van Herpen, Carla M. L.
    Queirolo, Paola
    Blank, Christian U.
    Hauschild, Axel
    Beck, J. Thaddeus
    St-Pierre, Annie
    Niazi, Faiz
    Wandel, Simon
    Peters, Malte
    Zubel, Angela
    Dummer, Reinhard
    LANCET ONCOLOGY, 2013, 14 (03) : 249 - 256
  • [36] CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
    Hodi, F. Stephen
    Amen, Asim
    Saenger, Yvonne M.
    Pennock, Gregory K.
    Guthrie, Troy H.
    Salama, April K.
    Flaherty, Lawrence E.
    Koon, Henry B.
    Lawson, David H.
    Shaheen, Montaser F.
    Balogh, Agnes
    Konto, Cyril
    O'Day, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
    Gogas, Helen
    Dummer, Reinhard
    Ascierto, Paolo A.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    Yamazaki, Naoya
    Loquai, Carmen
    Queirolo, Paola
    de Willem, Groot Jan
    Sellier, Abir Tadmouri
    Suissa, Jeanne
    Murris, Juliette
    Gollerkeri, Ashwin
    Robert, Caroline
    Flaherty, Keith T.
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 116 - 128
  • [38] A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.
    Ascierto, Paolo Antonio
    Bechter, Oliver
    Wolter, Pascal
    Lebbe, Celeste
    Elez, Elena
    Miller, Wilson H.
    Long, Georgina V.
    Omlin, Aurelius Gabriel
    Siena, Salvatore
    Calvo, Emiliano
    Pickard, Mike
    Gollerkeri, Ashwin
    Wollenberg, Lance
    Germa, Caroline
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
    Diab, Adi
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Ferry A. L. M.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Klempner, Samuel J.
    Ganguly, Bishu
    Fleener, Catherine
    Wang, Xiao
    Joh, Tenshang
    Liao, Ken
    Salek-Ardakani, Shahram
    Taylor, Carrie Turich
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 71 - 83
  • [40] Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma
    Chapman, P. B.
    Hauschild, A.
    Robert, C.
    Larkin, J. M. G.
    Haanen, J. B. A. G.
    Ribas, A.
    Hogg, D.
    O'Day, S.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P.
    Dummer, R.
    Sosman, J. A.
    Garbe, C.
    Lee, R. J.
    Nolop, K. B.
    Nelson, B.
    Hou, J.
    Flaherty, K. T.
    McArthur, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
12345